Epileptic Syndromes: Clinical Trials

28 trials for Epileptic Syndromes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 5 active not recruiting, 5 recruiting, 2 terminated. 28 Phase 1, 15 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 128Completed 13, Active not recruiting 5, Recruiting 5, Terminated 2, Unknown 2, Not yet recruiting 1
Phase 215Active not recruiting 5, Recruiting 5, Completed 3, Not yet recruiting 1, Terminated 1

Follow Epileptic Syndromes: new trials by email Literature Review of Epileptic Syndromes trials Research Report on Epileptic Syndromes

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
ION337 - Dravet Syndrome
Phase 1 / Phase 2RecruitingIonis Pharmaceuticals, Inc.322026-05-212026-11-02
Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation
nL-ATN1-001 - Dentatorubral-Pallidoluysian Atrophy
Phase 1 / Phase 2Active not recruitingn-Lorem Foundation12025-11-062026-04-07
Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies
Ketogenic diet - Developmental and Epileptic Encephalopathies, Epileptic Spasms
Phase 1TerminatedHeather Olson12025-08-112026-10-14
Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ)
Stiripentol capsule (Diacomit®), Stiripentol oral suspension (Diacomit®) - Dravet Syndrome, Epilepsy
Phase 1CompletedBiocodex242025-06-012025-09-16
CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome
CBD: GT4 Transdermal Delivery System - Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS)
Phase 1 / Phase 2Not yet recruitingAlexander Rotenberg252025-01-012024-12-18
A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease
ION283 - Lafora Disease
Phase 1 / Phase 2RecruitingBerge Minassian102024-12-032025-12-18
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
NRTX-1001 - Epilepsy, Temporal Lobe
Phase 1 / Phase 2RecruitingNeurona Therapeutics102024-11-142026-01-07
Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation
nL-ATN1-002 - Dentatorubral-Pallidoluysian Atrophy
Phase 1 / Phase 2Active not recruitingn-Lorem Foundation12024-10-242026-07-13
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
AAV9-hSyn1-miGRIK2 - Mesial Temporal Lobe Epilepsy
Phase 1 / Phase 2RecruitingUniQure Biopharma B.V.122024-06-122026-08-24
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
ETX101 - Dravet Syndrome
Phase 1 / Phase 2RecruitingEncoded Therapeutics1132024-05-142026-10-23
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
ETX101 - Dravet Syndrome
Phase 1 / Phase 2Active not recruitingEncoded Therapeutics52024-05-092026-06-08
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
ETX101 - Dravet Syndrome
Phase 1 / Phase 2Active not recruitingEncoded Therapeutics42024-02-282025-11-14
Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation
nL-ATN1-002 - Dentatorubral-Pallidoluysian Atrophy
Phase 1 / Phase 2Active not recruitingn-Lorem Foundation12024-02-212026-04-09
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies
Phase 1 / Phase 2CompletedChildren's Hospital of Philadelphia162023-09-222024-11-29
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK
AUT00201, Placebo - Myoclonus Epilepsies, Progressive
Phase 1CompletedAutifony Therapeutics Limited62023-05-122025-03-25
Exercise for Brain Regeneration in Epilepsy
High-Impact Aerobic Exercise, Low-Impact Aerobic Exercise - Temporal Lobe Epilepsy
Phase 1UnknownUniversity of Southern California102022-08-202023-12-06
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
LP352, Placebo - Developmental and Epileptic Encephalopathy, Dravet Syndrome
Phase 1 / Phase 2CompletedLongboard Pharmaceuticals522022-03-032024-11-08
Tricaprilin Infantile Spasms Pilot Study
Tricaprilin - Infantile Spasm
Phase 1CompletedCerecin82021-11-012024-09-19
Bioavailability and Food Effect Study of 3 Types of Carisbamate
Carisbamate - Healthy Subjects
Phase 1CompletedSK Life Science, Inc.332020-08-272021-10-07
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome
STK-001 - Single Ascending Doses, STK-001 - Multiple Ascending Doses - Dravet Syndrome
Phase 1 / Phase 2CompletedStoke Therapeutics, Inc622020-06-292025-05-18

Showing 20 of 28. Sign in to see all of them.

Narrower conditions

Epilepsies, Myoclonic (13)  ·  Lennox Gastaut Syndrome (8)  ·  Epilepsy (5)  ·  Myoclonic Epilepsies, Progressive (4)  ·  Spasms, Infantile (3)  ·  Drug Resistant Epilepsy (2)  ·  Epilepsy, Temporal Lobe (2)  ·  Generalized Epilepsy With Febrile Seizures Plus, Type 2 (2)  ·  Seizures (2)  ·  CDKL5 deficiency disorder (1)  ·  Epilepsy, Rolandic (1)  ·  Hippocampal Sclerosis (1)  ·  Lafora Disease (1)  ·  Landau-Kleffner Syndrome (1)

Broader conditions

Brain Diseases (28)  ·  Central Nervous System Diseases (28)  ·  Nervous System Diseases (28)  ·  Epilepsy (23)  ·  Epilepsy, Generalized (21)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11)  ·  Genetic Diseases, Inborn (10)  ·  Epilepsies, Myoclonic (6)  ·  Epilepsies, Partial (3)  ·  Congenital Abnormalities (2)  ·  Heredodegenerative Disorders, Nervous System (2)  ·  Malformations of Cortical Development (2)  ·  Malformations of Cortical Development, Group I (2)  ·  Myoclonic Epilepsies, Progressive (2)

Interventions

Cannabidiol (3)  ·  S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (3)  ·  Diet, Ketogenic (1)  ·  Levetiracetam (1)  ·  Medical Marijuana (1)  ·  Suspensions (1)  ·  stiripentol (1)  ·  tricaprylin (1)

Sponsors

Encoded Therapeutics (3)  ·  SK Life Science, Inc. (3)  ·  n-Lorem Foundation (3)  ·  Alexander Rotenberg (1)  ·  Autifony Therapeutics Limited (1)  ·  Berge Minassian (1)  ·  Biocodex (1)  ·  Cerecin (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Children's Hospital of Philadelphia (1)  ·  Epygenix (1)  ·  Gillette Children's Specialty Healthcare (1)  ·  Heather Olson (1)  ·  Ionis Pharmaceuticals, Inc. (1)  ·  Longboard Pharmaceuticals (1)

Countries

United States (23)  ·  Australia (4)  ·  Canada (2)  ·  United Kingdom (2)  ·  France (1)  ·  Singapore (1)

Top investigators

Marc Kamin, MD (2)  ·  Salvador Rico, M.D., Ph.D (2)  ·  Alexander Rotenberg, MD, PhD (1)  ·  Ann Dandurand, MD (1)  ·  Berge Minassian, MD (1)  ·  Beverly S Wical, MD (1)  ·  Colin VanOrman, MD (1)  ·  Dennis J Dlugos, MD (1)  ·  Eduardo Dunayevich, MD (1)  ·  Elizabeth M McCormick, MS (1)  ·  Francis Filloux, MD (1)  ·  Hahn-Jun Lee, Ph.D. (1)  ·  Jane Alcorn, PhD (1)  ·  Jennifer Vannest, PhD (1)

Results publications

PMID 27012680, PMID 27350662, PMID 31333569, PMID 41780062

NIH funding

R01NS065840 (1), U54NS078059 (1)